555 related articles for article (PubMed ID: 18376330)
1. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Stanković Z; Britvić D; Vuković O; Ille T
Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
[TBL] [Abstract][Full Text] [Related]
2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
4. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Stanković Z; Ille T
Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
[TBL] [Abstract][Full Text] [Related]
5. [Relationships between insight and medication adherence in subjects with psychosis].
Droulout T; Liraud F; Verdoux H
Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
[TBL] [Abstract][Full Text] [Related]
6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
7. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
8. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
9. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
10. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
11. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
12. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
[TBL] [Abstract][Full Text] [Related]
13. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
Kim JH; Kim SY; Ahn YM; Kim YS
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
15. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
Rocca P; Crivelli B; Marino F; Mongini T; Portaleone F; Bogetto F
Compr Psychiatry; 2008; 49(2):170-6. PubMed ID: 18243890
[TBL] [Abstract][Full Text] [Related]
16. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
[TBL] [Abstract][Full Text] [Related]
17. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
18. Clozapine maintenance therapy in schizophrenia.
Gaszner P; Makkos Z
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
[TBL] [Abstract][Full Text] [Related]
19. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Kim JH; Byun HJ
J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
